

Resource Summary Report

Generated by [T1D](#) on Sep 19, 2026

Bio X Cell

RRID:SCR_004997

Type: Tool

Proper Citation

Bio X Cell (RRID:SCR_004997)

Resource Information

URL: <https://bxccl.com/>

Proper Citation: Bio X Cell (RRID:SCR_004997)

Description: Commercial supplier and developer of in vivo antibodies. Provides antibodies and antibody production services.

Resource Type: commercial organization

Keywords: commercial, antibody, reagent, biomedical, research, new hampshire,

Resource Name: Bio X Cell

Resource ID: SCR_004997

Alternate IDs: SCR_019248, nlx_152318

Record Creation Time: 20220129T080227+0000

Record Last Update: 20260919T195045+0000

Ratings and Alerts

No rating or validation information has been found for Bio X Cell.

No alerts have been found for Bio X Cell.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4386 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Janakiraman M, et al. (2023) High salt diet does not impact the development of acute myeloid leukemia in mice. *Cancer immunology, immunotherapy* : CII, 72(1), 265.

Morehead LC, et al. (2023) Increased response to immune checkpoint inhibitors with dietary methionine restriction. *bioRxiv* : the preprint server for biology.

Gu Y, et al. (2023) Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases. *Signal transduction and targeted therapy*, 8(1), 273.

Lyons-Cohen MR, et al. (2023) Prolonged T cell - DC macro-clustering within lymph node microenvironments initiates Th2 cell differentiation in a site-specific manner. *bioRxiv* : the preprint server for biology.

Han SJ, et al. (2023) Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion. *Proceedings of the National Academy of Sciences of the United States of America*, 120(23), e2221707120.

Bhatnagar N, et al. (2023) Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination. *Vaccines*, 11(7).

Wu F, et al. (2023) Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer. *Experimental hematology & oncology*, 12(1), 67.

Azulay M, et al. (2023) Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading. *Journal of translational medicine*, 21(1), 222.

Cui L, et al. (2023) Innate immune cell activation causes lung fibrosis in a humanized model of long COVID. *Proceedings of the National Academy of Sciences of the United States of America*, 120(10), e2217199120.

Tian P, et al. (2023) Early life gut microbiota sustains liver-resident natural killer cells maturation via the butyrate-IL-18 axis. *Nature communications*, 14(1), 1710.

Solé P, et al. (2023) A T follicular helper cell origin for T regulatory type 1 cells. *Cellular & molecular immunology*, 20(5), 489.

Couvidou A, et al. (2023) Marginal zone B cells are responsible for the production of alloantibodies following platelet transfusion in mice. *Blood advances*, 7(8), 1356.

Osorio EY, et al. (2023) Malnutrition-related parasite dissemination from the skin in visceral leishmaniasis is driven by PGE2-mediated amplification of CCR7-related trafficking of infected inflammatory monocytes. *PLoS neglected tropical diseases*, 17(1), e0011040.

So L, et al. (2023) Regulatory T cells suppress CD4+ effector T cell activation by controlling protein synthesis. *The Journal of experimental medicine*, 220(3).

O'Brien BJ, et al. (2023) CD73-generated extracellular adenosine promotes resolution of neutrophil-mediated tissue injury and restrains metaplasia in pancreatitis. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 37(1), e22684.

Wang C, et al. (2023) Dendritic cells direct circadian anti-tumour immune responses. *Nature*, 614(7946), 136.

Edwards SC, et al. (2023) PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A-producing ?? T cells. *The Journal of experimental medicine*, 220(2).

Pfefferlé M, et al. (2023) Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity. *Journal for immunotherapy of cancer*, 11(1).

Ding L, et al. (2023) Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. *The Journal of clinical investigation*, 133(1).

Gajendran C, et al. (2023) Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer. *PloS one*, 18(1), e0279063.